Summarized by Masters of Longevity from Nature - Main.
Pancreatic-cancer research coverage that previews how early-detection and novel drug strategies are being explored to intercept tumours before they progress.
Key Takeaways
- The FDA recently approved daraxonrasib for pancreatic cancer, renewing interest in interception strategies.
- The PRECEDE study has enrolled over 12,000 high-risk participants and diagnosed more than 50 early-stage pancreatic cancers.
- Mouse studies show KRAS-targeting drugs can shrink precancerous pancreatic lesions and improve survival in animals.
